ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Lifted by Lazard Asset Management LLC

Lazard Asset Management LLC lifted its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 38.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 348,599 shares of the biotechnology company's stock after acquiring an additional 96,689 shares during the period. Lazard Asset Management LLC owned 0.15% of ADMA Biologics worth $5,977,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Mark Sheptoff Financial Planning LLC purchased a new position in shares of ADMA Biologics during the 4th quarter worth $35,000. Vision Financial Markets LLC purchased a new stake in ADMA Biologics in the 4th quarter valued at about $51,000. AlphaQuest LLC purchased a new stake in ADMA Biologics in the 4th quarter valued at about $84,000. CIBC Private Wealth Group LLC raised its holdings in ADMA Biologics by 137.1% in the 4th quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock valued at $95,000 after buying an additional 2,954 shares during the period. Finally, Jones Financial Companies Lllp raised its holdings in ADMA Biologics by 303.4% in the 4th quarter. Jones Financial Companies Lllp now owns 5,733 shares of the biotechnology company's stock valued at $98,000 after buying an additional 4,312 shares during the period. Hedge funds and other institutional investors own 75.68% of the company's stock.

Analyst Ratings Changes

ADMA has been the topic of several research analyst reports. StockNews.com lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James boosted their price objective on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $24.25.

ADMA Biologics Price Performance

ADMA Biologics stock traded down $0.08 during midday trading on Wednesday, reaching $20.36. The company's stock had a trading volume of 433,877 shares, compared to its average volume of 3,693,675. ADMA Biologics, Inc. has a fifty-two week low of $9.31 and a fifty-two week high of $25.67. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock's 50 day simple moving average is $20.52 and its 200 day simple moving average is $18.88. The firm has a market capitalization of $4.86 billion, a PE ratio of 72.61 and a beta of 0.57.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.16 by ($0.02). ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $114.80 million during the quarter, compared to analysts' expectations of $116.40 million. During the same quarter in the prior year, the business earned $0.08 EPS. The company's quarterly revenue was up 40.2% compared to the same quarter last year. On average, equities research analysts forecast that ADMA Biologics, Inc. will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.